Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07408440 · ClinicalTrials.gov registry record · NA
Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause
A NA study, sponsored by The University of Texas Health Science Center, Houston.
- Not yet
- Registry status
- NA
- Development phase
- 150
- Enrollment target
NCT07408440: Clinical Trial NA study, sponsored by The University of Texas Health Science Center, Houston.
NCT07408440 is a NA study that has not yet begun recruiting, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 150 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07408440, a NA study, has not yet begun recruiting, sponsored by The University of Texas Health Science Center, Houston.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
Study Summary
Hypoactive sexual desire disorder (HSDD) is described as the most common form of female sexual dysfunction, particularly affecting peri- and postmenopausal women and is associated with significant distress and reduced quality of life. The TESTA-MIND study will evaluate the efficacy and safety of a standardized compounded transdermal testosterone gel in a randomized, double-blind, placebo-controlled design to address the lack of FDA-approved options and limited high-quality evidence for treating decreased libido in women.
Primary Outcome
The Female Sexual Function Index (FSFI) is a widely used, 19-item self-report questionnaire assessing women's sexual health across six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. Responses are rated on scales (1-5), with higher scores indicating better function, and these are combined to form domain and total scores.
Interventions
- OTHER Transdermal testosterone gel
- OTHER Transdermal placebo gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2028-03-30 |
| Phase | NA |
What is known before NCT07408440 opens enrollment
NCT07408440 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Transdermal testosterone gel is the first listed.
NCT07408440 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07408440 about?
NCT07408440 is a clinical study titled "Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause". Hypoactive sexual desire disorder (HSDD) is described as the most common form of female sexual dysfunction, particularly affecting peri- and postmenopausal women and is associated with significant distress and reduced quality of life. The TESTA-MIND study will evaluate the efficacy and safety of a s...
What is the current status of trial NCT07408440?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2026-04-01. Estimated completion is 2028-03-30.
What interventions are being tested in trial NCT07408440?
The interventions under investigation include: Transdermal testosterone gel (OTHER), Transdermal placebo gel (OTHER).
Who is sponsoring clinical trial NCT07408440?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07408440's enrollment target sits among peer trials
150 661st of 2000 higher than 1,299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI